Applied Genetic Technologies (AGTC) announced Thursday morning that it has entered into a broad collaboration and license agreement with Biogen (BIIB) to develop gene-based therapies for ophthalmic diseases.
Applied Genetic Technologies gapped up sharply Thursday, but was range-bound throughout the session. Shares finished with a gain of 2.77 at $19.03 on the highest volume of the year. The stock jumped to a 2-week high and re-crossed its 50-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News